 |
5 Diseases |  |
7 Trials |
|
7 Trials |  |
34 News |  |
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New trial: Safety and efficacy of Retagliptin in Chinese patients with type 2 diabetes. (EUDRACT) - Apr 2, 2025
P=N/A, N=2500, Recruiting, Sponsor: The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P4 trial: Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients (clinicaltrials.gov) - May 16, 2024
P4, N=160, Not yet recruiting, Sponsor: Peking University First Hospital
- ||| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Clinical, P3 data, Journal: Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial. (Pubmed Central) - Apr 15, 2024
For patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy, the co-administration of retagliptin and henagliflozin yielded more effective glycaemic control through 24?weeks compared with the individual agents at their corresponding doses.
- ||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Clinical, P3 data, Journal: Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. (Pubmed Central) - Apr 11, 2024
For patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy, the co-administration of retagliptin and henagliflozin yielded more effective glycaemic control through 24?weeks compared with the individual agents at their corresponding doses. Retagliptin 100?mg QD as an add-on therapy to metformin offers a new therapeutic option for treating Chinese patients with T2D inadequately controlled by metformin alone, and is generally well tolerated.
- || Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: A Trial of SP2086 With Hepatic Insufficiency (clinicaltrials.gov) - Sep 13, 2023
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Jul 10, 2023
P3, N=174, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Retagliptin 100?mg QD as an add-on therapy to metformin offers a new therapeutic option for treating Chinese patients with T2D inadequately controlled by metformin alone, and is generally well tolerated. Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Dec 2023
- |||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy: Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Jun 13, 2022
P3, N=160, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- || Januvia (sitagliptin) / Merck (MSD)
PK/PD data, Journal: High-throughput bioanalysis of sitagliptin in plasma using the Direct Analysis in Real Time mass spectrometry and its application in the pharmacokinetic study thereof. (Pubmed Central) - Apr 8, 2022
This method has been successfully applied to the pharmacokinetic study of sitagliptin after single intravenous administration in rats. This approach shows considerable promise of Direct Analysis in Real Time tandem mass spectrometry method in the high-throughput bioanalysis.
- |||||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Combination therapy: Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Sep 23, 2021
P3, N=160, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Monotherapy: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy (clinicaltrials.gov) - Dec 13, 2020
P3, N=760, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers (clinicaltrials.gov) - Jul 7, 2016
P1, N=30, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers (clinicaltrials.gov) - Jul 5, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients (clinicaltrials.gov) - Jul 5, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The DDI Study of SP2086 and Valsartan (clinicaltrials.gov) - Jun 29, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The DDI Study of SP2086 and Simvastatin (clinicaltrials.gov) - Jun 29, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SP2086 and Valsartan (clinicaltrials.gov) - Jun 28, 2016
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SP2086 and Simvastatin (clinicaltrials.gov) - Jun 28, 2016
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Metabolite Identification and Material Balance Study of SP2086 (clinicaltrials.gov) - Jun 28, 2016
P1, N=8, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: SP2086 Pharmacokinetic Study in Renal Insufficiency Patients (clinicaltrials.gov) - Jun 28, 2016
P1, N=30, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug -Drug Interaction of SP2086 and Glyburide (clinicaltrials.gov) - Jun 28, 2016
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SP2086 and Metformin (clinicaltrials.gov) - Jun 27, 2016
P1, N=24, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Trial primary completion date: The Drug-drug Interaction of SHR3824 and SP2086 (clinicaltrials.gov) - Nov 25, 2015
P1, N=12, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This approach shows considerable promise of Direct Analysis in Real Time tandem mass spectrometry method in the high-throughput bioanalysis. Trial primary completion date: Oct 2015 --> Jul 2015
- Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SHR3824 and SP2086 (clinicaltrials.gov) - Jul 16, 2015
P1, N=12, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy: A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 21, 2013
P3, N=360, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Oct 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- |||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Enrollment open, Monotherapy: Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 21, 2013
P3, N=450, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Trial completion: A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes (clinicaltrials.gov) - Oct 20, 2013
P2, N=200, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
Trial completion, Combination therapy: Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 20, 2013
P2, N=120, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed Not yet recruiting --> Completed
- |||||||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Combination therapy: A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 17, 2013
P3, N=360, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Monotherapy: Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 17, 2013
P3, N=450, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P2 trial: A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes (clinicaltrials.gov) - Oct 16, 2013
P2, N=200, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy: Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 16, 2013
P2, N=120, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.